Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations
暂无分享,去创建一个
S. Humphries | J. Cooper | K. Bauer | R. Rosenberg | G. Miller | S. Humphries | S. Barzegar | B. Smillie | J. Cooper | R. Rosenberg | L. Li | Lily Li
[1] K. Mann,et al. "Normal" thrombin generation. , 1999, Blood.
[2] M. Woodward,et al. Activated Protein C Resistance and the FV:R506Q Mutation in a Random Population Sample , 1999, Thrombosis and Haemostasis.
[3] S. Béguin,et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[4] P. Reitsma,et al. Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.
[5] J. Cooper,et al. Activation of the Coagulant Pathway in Cigarette Smokers , 1998, Thrombosis and Haemostasis.
[6] J. Corral,et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease , 1997, British journal of haematology.
[7] F R Rosendaal,et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. , 1997, Blood.
[8] K. Mann,et al. Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * , 1997, The Journal of Biological Chemistry.
[9] T. Raghunathan,et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. , 1997, Blood.
[10] P. Reitsma,et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.
[11] D. Ardissino,et al. Factor V (Arg506⟶ Gln) Mutation in Young Survivors of Myocardial Infarction , 1996, Thrombosis and Haemostasis.
[12] R. Ford,et al. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. , 1996, Journal of immunoassay.
[13] P. Mannucci,et al. Heightened Thrombin Generation in Individuals with Resistance to Activated Protein C , 1996, Thrombosis and Haemostasis.
[14] B. Dahlbäck,et al. Elevated Levels of Prothrombin Activation Fragment 1+2 in Plasma from Patients with Heterozygous Arg506 to Gin Mutation in the Factor V Gene (APC-Resistance) and/or Inherited Protein S Deficiency , 1996, Thrombosis and Haemostasis.
[15] P. Simioni,et al. Prothrombin fragment 1+2 and thrombin–antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation , 1996, British journal of haematology.
[16] S. Humphries,et al. High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). , 1995, BioTechniques.
[17] J. Griffin,et al. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. , 1995, Blood.
[18] P. Ridker,et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.
[19] K. Mann,et al. Characterization of the Molecular Defect in Factor VR506A(*) , 1995, The Journal of Biological Chemistry.
[20] A. Schafer. Hypercoagulable states: molecular genetics to clinical practice , 1994, The Lancet.
[21] B. Dahlbäck,et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. , 1994, The Journal of clinical investigation.
[22] S. Humphries,et al. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. , 1994, Analytical biochemistry.
[23] J. Voorberg,et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.
[24] B. Evatt,et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.
[25] Pieter H. Reitsma,et al. Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.
[26] J. Miletich,et al. Inherited predisposition to thrombosis , 1993, Cell.
[27] P. Mannucci,et al. Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes , 1992, Thrombosis and Haemostasis.
[28] W. Stüber,et al. Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.
[29] H. ten Cate,et al. Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.
[30] M. Bednarek,et al. DETECTION OF FACTOR X ACTIVATION IN HUMANS , 1989, Thrombosis and Haemostasis.
[31] R. Bertina,et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. , 1988, Blood.
[32] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[33] K. Bauer,et al. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. , 1982, Blood.
[34] F R Rosendaal,et al. Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .
[35] J. Miletich. Thrombophilia as a multigenic disorder. , 1998, Seminars in thrombosis and hemostasis.
[36] D. Ardissino,et al. Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. , 1996, Thrombosis and haemostasis.
[37] J. Cooper,et al. The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.
[38] G. Miller,et al. Factor VII-Deficient Substrate Plasmas Depleted of Protein C Raise the Sensitivity of the Factor VII Bio-Assay to Activated Factor VII: an International Study , 1994, Thrombosis and Haemostasis.
[39] P. Comp,et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.
[40] J. Griffin,et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. , 1993, Blood.